share_log

Theriva Biologics FY EPS $(1.14) Beats $(1.28) Estimate; As Of December 31, 2023, Theriva Biologics Reports $23.2M In Cash, Which Is Expected To Provide Runway Into The First Quarter Of 2025

Moomoo 24/7 ·  Mar 25 07:32

Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(1.14) per share which beat the analyst consensus estimate of $(1.28) by 10.94 percent. This is a 12.98 percent increase over losses of $(1.31) per share from the same period last year.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment